2025-04-13 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**0. Key Figures Summary:**

* **MRK Cumulative Return:** 8.48%
* **VOO (S&P 500) Cumulative Return:** 66.36%
* **Return Difference:** -57.9%
* **Relative Divergence:** 21.7% (Indicates MRK's performance is relatively lower than VOO, but not at its historical worst)
* **Current Price:** $79.18
* **RSI:** 25.78 (Suggests oversold conditions)
* **PPO:** -1.26 (Indicates bearish momentum)
* **Expected Return (Long-Term):** -35.3% (relative to S&P 500)


**1. Performance Comparison & Company Overview:**

Merck & Co Inc (MRK) is a leading pharmaceutical company focused on research, development, manufacturing, and marketing of innovative prescription medicines and vaccines.

MRK's cumulative return significantly underperformed the S&P 500 (VOO) over the analyzed period, lagging by 57.9 percentage points.  While this underperformance is substantial, the relative divergence of 21.7% suggests that this is not the worst underperformance MRK has experienced historically.


**Alpha & Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 5.0% | 58.4% | -24.0% | 0.0 | 108.6 |
| 2016-2018  | 42.0% | 66.6% | 24.0% | 0.1 | 151.9 |
| 2017-2019  | 40.0% | 66.6% | 11.0% | 0.2 | 185.8 |
| 2018-2020  | 19.0% | 66.6% | -6.0% | 0.4 | 172.4 |
| 2019-2021  | -1.0% | 65.6% | -55.0% | 0.5 | 175.4 |
| 2020-2022  | 13.0% | 69.3% | 7.0% | 0.5 | 262.1 |
| 2021-2023  | 35.0% | 69.3% | 19.0% | 0.3 | 264.8 |
| 2022-2024  | -6.0% | 69.3% | -23.0% | 0.3 | 248.2 |
| 2023-2025  | -45.0% | 70.3% | -59.0% | 0.2 | 199.2 |

The data shows significant volatility in MRK's performance, with both high CAGR and MDD values across different periods.  Alpha values fluctuate, suggesting periods of both outperformance and underperformance relative to the market. Beta generally remains below 1, indicating lower than average market volatility.


**2. Recent Price Movement:**

* **Closing Price:** $79.18
* **5-day Moving Average:** $79.75
* **20-day Moving Average:** $87.33
* **60-day Moving Average:** $90.20

The price is below all three moving averages, suggesting a downtrend.  The recent price increase (from $77.55 to $79.18) is relatively small compared to the moving averages, so it's not yet a strong indication of a trend reversal.


**3. Technical Indicators & Market Risk:**

* **Market Risk Indicator (MRI):** 0.47 (High Risk)
* **RSI:** 25.78 (Oversold)
* **PPO:** -1.26 (Bearish Momentum)
* **Recent Relative Divergence:** -10.5% (Short-term downtrend)
* **Expected Return (Long-Term):** -35.3% (vs. S&P 500)

The combination of high MRI, low RSI, negative PPO, and negative relative divergence points to a bearish outlook.  The recent small price increase is not sufficient to change this outlook. The projected long-term underperformance against the S&P 500 is a significant concern.


**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2024-11-06 | 1.25 | $16.66 B      |
| 2024-08-05 | 2.15 | $16.11 B      |
| 2024-05-03 | 1.88 | $15.78 B      |
| 2023-11-03 | 1.87 | $15.96 B      |
| 2024-11-06 | 1.87 | $15.96 B      | *(Duplicate entry - possible data error)*

There's a significant fluctuation in EPS, with a noticeable drop in the most recent quarter.  Revenue remains relatively stable, but further analysis is needed to determine the underlying causes of the EPS volatility.  The duplicate entry on 2024-11-06 needs clarification.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |
| 2023-12-31 | $14.63B | 73.26% |

Revenue shows some fluctuation but generally remains within a similar range. Profit margins are high and relatively stable, although a slight downward trend is visible.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |
| 2024-06-30 | $43.58B | 12.52% |
| 2024-03-31 | $40.36B | 11.80% |
| 2023-12-31 | $37.58B | -3.26% |

Equity is steadily increasing, but ROE shows considerable variation, even dipping into negative territory in 2023.  This volatility in ROE requires further investigation.


**6. Overall Conclusion:**

MRK's recent performance has been significantly weaker than the S&P 500.  Technical indicators suggest an oversold market and bearish momentum.  While the company maintains high profit margins, recent earnings data shows volatile EPS, and ROE demonstrates significant fluctuation. The projected long-term underperformance relative to the S&P 500 is a key concern.  Further investigation is needed to understand the drivers of the recent volatility in both earnings and ROE.  Investors considering a long-term investment should carefully weigh the risks associated with this underperformance and volatile financial metrics.  The data suggests a cautious approach is warranted.  A thorough review of the company's future pipeline and strategic initiatives would be crucial for a more informed decision.
